Should DPD analysis be required prior to prescribing fluoropyrimidines?

Eur J Cancer. 2007 Apr;43(6):1011-6. doi: 10.1016/j.ejca.2007.01.030. Epub 2007 Mar 12.

Abstract

Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolic catabolism of chemotherapeutic agent 5-fluorouracil (5FU) and its derivatives, including capecitabine. Numerous genetic mutations have been identified in the DPD gene locus (DPYD), with a few key variants having functional consequences on enzymatic activity. Deficiencies in DPD activity have been shown to cause 5FU-treated cancer patients to experience severe drug-related toxicities, often requiring extensive medical intervention. We review the performance of assays that assess DPD and DPYD status, with an emphasis on the robustness for routine clinical applications. None of the current strategies are adequate to mandate routine DPD testing prior to starting a fluoropyrimidine-based therapy. However, further research and technological improvements will hopefully allow prospective identification of potentially toxic patients, in order to reduce the number of patients with severe, life-threatening side effects to 5FU treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antimetabolites, Antineoplastic / adverse effects*
  • Chromatography, High Pressure Liquid / methods
  • DNA Mutational Analysis / methods
  • Dihydropyrimidine Dehydrogenase Deficiency
  • Dihydrouracil Dehydrogenase (NADP) / analysis
  • Dihydrouracil Dehydrogenase (NADP) / genetics*
  • Fluorouracil / adverse effects*
  • Humans
  • Mutation / genetics*
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology
  • Reverse Transcriptase Polymerase Chain Reaction / methods

Substances

  • Antimetabolites, Antineoplastic
  • Dihydrouracil Dehydrogenase (NADP)
  • Fluorouracil